2065 |
ERB-B2 RECEPTOR TYROSINE KINASE 3 |
ERBB3 |
ErbB-3 |
HER3 |
LCCS2 |
MDA-BF-1 |
c-erbB-3 |
c-erbB3 |
erbB3-S |
p180-ErbB3 |
p45-sErbB3 |
p85-sErbB3 |
190151 |
3431 |
ENSG00000065361 |
OTTHUMG00000170140 |
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 PRECURSOR (EC 2.7.1.112) (C- ERBB3) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER3). [SOURCE:UNIPROT/SWISSPROT;ACC:P21860] |
1733 |
P21860 |
Receptor tyrosine-protein kinase erbB-3 |
Proto-oncogene-like protein c-ErbB-3 |
Tyrosine kinase-type cell surface receptor HER3 |
ERBB3_HUMAN |
EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER3 (ERBB3) |
HER3 (ERBB3) |
PA27846 |
Erbb3 tyrosine kinase receptor |
T86350 |
FERLK |
VSCN1 |
Human Readable Name | DRUGGABLE GENOME |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Interpro Type | Domain |
Uniprot Status | Swiss-Prot |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Human Readable Name | KINASE |
Interpro Acc | IPR001245 |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
ENZYME |
antibody (inhibitory) |
antagonist (inhibitory) |
Mechanism of Interaction | Receptor tyrosine-protein kinase erbB-3 antagonist |
Direct Interaction | yes |
antibody (inhibitory) |
Notes |
antibody (inhibitory) |
Trial Name | MM-111 |
Novel drug target | Novel Target |
inhibitor (inhibitory) |
Mechanism of Interaction | Receptor tyrosine-protein kinase erbB-3 inhibitor |
Direct Interaction | yes |
Notes |
antibody (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Receptor tyrosine-protein kinase erbB-3 inhibitor |
n/a |
antibody (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
antibody (inhibitory) |
antibody (inhibitory) |
n/a |
Trial Name | AC480 |
Novel drug target | Novel Target |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Epidermal growth factor receptor inhibitor |
Direct Interaction | yes |
ERBB3 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
P21860 | Uniprot Accession |
ERBB3 | Uniprot Gene Name |
ENSG00000065361 | Ensembl Gene Id |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Human Readable Name | DRUGGABLE GENOME |
KINASE, DRUGGABLE GENOME |
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 PRECURSOR (EC 2.7.1.112) (C- ERBB3) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER3). [SOURCE:UNIPROT/SWISSPROT;ACC:P21860] | Description |
ERBB3 | Display Id |
ENSG00000065361 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
ERBB3 | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
PA27846 | PharmGKB ID |
2065 | Entrez Gene ID |
1733 | CIViC Gene ID |
DRUG RESISTANCE |
Erbb-3 | TTD Gene Abbreviation |
T86350 | TTD Target ID |
HER3 | GENE_SYMBOL |
ERBB3 | GENE_SYMBOL |
Receptor tyrosine-protein kinase erbB-3 | UNIPROT |
ENSG00000065361 | Gene Symbol |
ERBB3 | Ensembl Id |
DRUGGABLE GENOME |
2065 | Entrez Gene Id |
ERBB3 | MyCancerGenome Gene Symbol |
HER3 (ERBB3) | MyCancerGenome Reported Gene Name |
HER3 | Gene Symbol |
ENSG00000065361 | Ensembl Gene ID |
HER3 | Human Protein Atlas Gene Synonym |
LCCS2 | Human Protein Atlas Gene Synonym |
ENZYME |
HER3 | GO Gene Synonym |
TYROSINE KINASE |
ERBB3 | Gene Symbol |
CLINICALLY ACTIONABLE |
2065 | Gene ID |
ErbB-3 | dGene Synonym |
HER3 | dGene Synonym |
KINASE, TYROSINE KINASE |
Receptor tyrosine-protein kinase erbB-3 | Gene Name |
P21860 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |